Synonyms: Anthim® | ETI-204 | Nyxthracis®
obiltoxaximab is an approved drug (FDA (2016), EMA (2020))
Compound class:
Antibody
Comment: Obiltoxaximab is a chimeric IgG1 kappa monoclonal antibody that binds the protective antigen (PA) component of Bacillus anthracis toxin.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes. FDA (2016) | EMA (2020) |
International Nonproprietary Names ![]() |
|
INN number | INN |
9825 | obiltoxaximab |
Synonyms ![]() |
Anthim® | ETI-204 | Nyxthracis® |
Database Links ![]() |
|
Specialist databases | |
Antibiotic DB
![]() |
Obiltoxaximab (Anthim) |
IMGT/mAb-DB | 549 |
Other databases | |
CAS Registry No. | 1351337-07-9 (source: Scifinder) |
ChEMBL Ligand | CHEMBL3544926 |
DrugBank Ligand | DB05336 |
GtoPdb PubChem SID | 496703312 |
Search PubMed clinical trials | obiltoxaximab |
Search PubMed titles | obiltoxaximab |
Search PubMed titles/abstracts | obiltoxaximab |